Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CTMX 
CytomX Therapeutics Inc (CTMX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: CTMX (3-star) is a REGULAR-BUY. BUY since 46 days. Profits (211.25%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 2 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 63.61% | Avg. Invested days 29 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 378.11M USD | Price to earnings Ratio 5 | 1Y Target Price 5.5 |
Price to earnings Ratio 5 | 1Y Target Price 5.5 | ||
Volume (30-day avg) 6 | Beta 2.12 | 52 Weeks Range 0.40 - 3.10 | Updated Date 07/9/2025 |
52 Weeks Range 0.40 - 3.10 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 28.2% | Operating Margin (TTM) 44.43% |
Management Effectiveness
Return on Assets (TTM) 15.87% | Return on Equity (TTM) -5475.03% |
Valuation
Trailing PE 5 | Forward PE 7.27 | Enterprise Value 306369485 | Price to Sales(TTM) 2.56 |
Enterprise Value 306369485 | Price to Sales(TTM) 2.56 | ||
Enterprise Value to Revenue 2.08 | Enterprise Value to EBITDA 8.14 | Shares Outstanding 157544000 | Shares Floating 60863433 |
Shares Outstanding 157544000 | Shares Floating 60863433 | ||
Percent Insiders 0.83 | Percent Institutions 51.02 |
Upturn AI SWOT
CytomX Therapeutics Inc
Company Overview
History and Background
CytomX Therapeutics, Inc. was founded in 2008. It focuses on developing probody therapeutics, designed to target cancer cells while minimizing impact on healthy tissue. The company has evolved through partnerships and clinical trials to advance its pipeline.
Core Business Areas
- Probody Therapeutics: Development of masked antibodies (Probody therapeutics) that are activated in the tumor microenvironment, reducing off-target toxicity. This includes research, preclinical development, and clinical trials.
- Immuno-Oncology: Focusing on immuno-oncology targets to stimulate the patient's immune system against cancer cells. This often involves combination therapies.
- Antibody-Drug Conjugates (ADCs): Developing ADCs using its probody technology, delivering cytotoxic payloads directly to cancer cells.
Leadership and Structure
Sean McCarthy is the CEO. The company structure includes research and development, clinical operations, and corporate functions like finance and legal.
Top Products and Market Share
Key Offerings
- CX-2029 (Probody ADC targeting CD71): CX-2029 is an ADC targeting CD71, a receptor overexpressed in many cancers. It is in clinical development. There is no current market share as it's pre-commercial. Competitors include companies developing similar ADCs, such as Daiichi Sankyo, Seagen (now part of Pfizer), and Immunomedics (now part of Gilead).
- CX-904 (Probody T-cell Engaging Bispecific): CX-904 is a conditionally active T-cell engaging bispecific antibody targeting EGFR on tumor cells and CD3 on T cells. It is in clinical development. There is no current market share as it's pre-commercial. Competitors include companies developing similar bispecific antibodies, such as Amgen and Roche.
Market Dynamics
Industry Overview
The oncology market is large and competitive, driven by unmet needs and technological advancements. Immuno-oncology and targeted therapies like ADCs are major growth areas. There is intense competition and rapid innovation.
Positioning
CytomX is positioned as an innovator in the field of conditionally activated antibodies, aiming to improve the safety and efficacy of cancer therapies. Its competitive advantage lies in its Probody technology.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be over $200 billion. CytomX is targeting specific niches within this market with its Probody platform, aiming to capture a share of the ADC and immuno-oncology segments.
Upturn SWOT Analysis
Strengths
- Proprietary Probody technology
- Potential for reduced off-target toxicity
- Strong partnerships with pharmaceutical companies
- Focus on innovative cancer therapies
Weaknesses
- Clinical development risk
- Dependence on partnerships for funding
- Limited number of commercialized products
- Competition from established players
Opportunities
- Expansion of Probody technology to new targets
- Potential for combination therapies
- Growth in the ADC market
- Increased demand for safer and more effective cancer treatments
Threats
- Clinical trial failures
- Competition from other drug developers
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- PFE
- BMY
- MRK
Competitive Landscape
CytomX's probody technology provides a potential advantage in terms of safety and efficacy. However, it faces competition from larger companies with more resources and established products.
Major Acquisitions
No acquisitions to report
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: None
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the advancement of its pipeline and the signing of collaboration agreements. However, the company has not yet achieved profitability.
Future Projections: Future growth depends on the success of its clinical trials and its ability to secure additional partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials of its lead programs (CX-2029, CX-904) and expanding its collaboration with BMS.
Summary
CytomX Therapeutics is an innovative company developing Probody therapeutics. Their Probody platform is designed to improve the safety and efficacy of cancer treatments, but has had limited success in the market and only a small market share. Clinical trial successes and securing partnerships are key to future growth. The company needs to mitigate risks associated with clinical development and competition from established players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- CytomX Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CytomX Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2015-10-08 | Chairman & CEO Dr. Sean A. McCarthy DPHIL | ||
Sector Healthcare | Industry Biotechnology | Full time employees 119 | Website https://www.cytomx.com |
Full time employees 119 | Website https://www.cytomx.com | ||
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.